NASDAQ · LITS
Healthcare · Biotechnology
$1.08
Up+$0.04 (+3.85%)
Updated Nov 5, 2026, 3:43 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LITS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
LITS closed at $1.08 after 21 trading sessions, down 14.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $1.05 | $1.12 | $1.05 | $1.08 | 145.01K |
| Nov 3, 2026 | $1.00 | $1.07 | $1.00 | $1.04 | 190.02K |
| Nov 2, 2026 | $1.11 | $1.16 | $0.95 | $0.9677 | 729.8K |
| Oct 30, 2026 | $1.17 | $1.17 | $1.10 | $1.12 | 270.47K |
| Oct 29, 2026 | $1.22 | $1.22 | $1.16 | $1.17 | 341.05K |
| Oct 28, 2026 | $1.16 | $1.23 | $1.15 | $1.23 | 297.76K |
| Oct 27, 2026 | $1.12 | $1.165 | $1.11 | $1.155 | 105.23K |
| Oct 26, 2026 | $1.15 | $1.175 | $1.11 | $1.12 | 163.45K |
| Oct 23, 2026 | $1.19 | $1.21 | $1.16 | $1.16 | 141.13K |
| Oct 22, 2026 | $1.23 | $1.23 | $1.175 | $1.19 | 168.96K |
| Oct 21, 2026 | $1.21 | $1.27 | $1.20 | $1.24 | 165.22K |
| Oct 20, 2026 | $1.16 | $1.23 | $1.13 | $1.19 | 225.25K |
| Oct 19, 2026 | $1.15 | $1.18 | $1.15 | $1.16 | 190.79K |
| Oct 16, 2026 | $1.20 | $1.211 | $1.135 | $1.15 | 116.19K |
| Oct 15, 2026 | $1.15 | $1.21 | $1.13 | $1.195 | 317.86K |
| Oct 14, 2026 | $1.20 | $1.20 | $1.15 | $1.17 | 281.21K |
| Oct 13, 2026 | $1.23 | $1.24 | $1.195 | $1.21 | 294.36K |
| Oct 12, 2026 | $1.26 | $1.275 | $1.21 | $1.22 | 271.26K |
| Oct 9, 2026 | $1.25 | $1.305 | $1.24 | $1.27 | 539.93K |
| Oct 8, 2026 | $1.30 | $1.30 | $1.18 | $1.22 | 982.81K |
| Oct 7, 2026 | $1.30 | $1.33 | $1.27 | $1.27 | 787.28K |
The latest Smart Investors Daily articles mentioning LITS.
Company
Market Activity
Research & News
LITS research
Company profile and research snapshot.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 17, 2026
Fifteen years after launching as Bitcoin's faster, cheaper sibling, Litecoin faces a hard question about whether it has grown into its own or simply fallen behind. The 2027 halving looms as a potential turning point, but history suggests the answer may not be what Litecoin holders are hoping for.
Benzinga · Sep 28, 2026
Lite Strategy (NASDAQ:LITS) reported quarterly losses of $(0.38) per share. This is a 5 percent increase over losses of $(0.40) per share from the same period last year.
Benzinga · Sep 28, 2026
https://www.sec.gov/Archives/edgar/data/1262104/000119312526405423/lits-20260928.htm
Benzinga · Jul 30, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LITS.
